FDA seizes Xiadafil VIP tablets due to potential drug injuries
July 29, 2008
Xiadafil VIP tablets, which were given away at trade shows and distributed by SEI Pharmaceuticals, Inc., contain an ingredient similar to Sildenafil, which is the active ingredient in Viagra for treatment of ED.
Xiadafil VIP has not been FDA approved for treatment of ED or any other drug use and therefore could cause potential drug injuries.
Because Xiadafil VIP has not been FDA approved for safety and effectiveness, its potential for national and Texas drug injuries is unknown.